HPTN Archives | Be Korea-savvy

Home / Posts tagged HPTN

Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study

DURHAM, N.C., July 28 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November 5, 2020, through [...]

HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention

DURHAM, N.C., Dec. 21 (Korea Bizwire) — Data from the HIV Prevention Trials Network (HPTN) studies HPTN 083 and HPTN 084 helped provide important information for yesterday’s decision by the U.S. Food and Drug Administration (FDA) to approve ViiV Healthcare’s long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. Sponsored and co-funded by the National [...]

HIV Prevention Trials Network Awarded U.S. National Institutes of Health Funding to Continue Research Agenda

DURHAM, N.C., Nov. 30 (Korea Bizwire) — Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network. The core and [...]

HPTN 084 Study Demonstrates Superiority of CAB LA to Oral FTC/TDF for the Prevention of HIV

Durham, N.C., Nov. 9 (Korea Bizwire) — Researchers from the HIV Prevention Trials Network (HPTN) announced today data from the HPTN 084 clinical trial indicate that a pre-exposure prophylaxis (PrEP) regimen of long-acting cabotegravir (CAB LA) injections once every eight weeks was safe and superior to daily oral tenofovir/emtricitabine (FTC/TDF) for HIV prevention among cisgender women in sub-Saharan Africa. During a planned review of study data, an independent Data and Safety Monitoring Board (DSMB) recommended the study sponsor―the National Institute of Allergy and Infectious Diseases [...]